On 5 September 2008, orphan designation (EU/3/08/560) was granted by the European Commission to KeyNeurotek Pharmaceuticals AG, Germany, for (-)-(2R)-3-(2-hydroxymethylindanyl-4-oxy)-phenyl-4,4,4-trifluorobutane-1-sulfonate for the treatment of moderate and severe closed traumatic brain injury.
For a list of the administrative updates to this public summary of opinion please refer to the PDF document below.
Treatment of moderate and severe closed traumatic brain injury
|Orphan designation status||
|EU designation number||
|Date of designation||
KeyNeurotek Pharmaceuticals AG
Tel. + 49 391 6117 220
Gax: + 49 391 6117 221
Documents related to this orphan designation evaluation
EU/3/08/560: Public summary of positive opinion for orphan designationof (-)-(2R)-3-(2-hydroxymethylindanyl-4-oxy)-phenyl-4,4,4-trifluorobutane-1-sulfonate for the treatment of moderate and severe closed traumatic brai... (PDF/103.91 KB)
First published: 24/04/2009
Last updated: 28/11/2013
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: